CORRECTED FREEDOM OF INFORMATION
SUMMARY
ORIGINAL NEW ANIMAL DRUG APPLICATION

NADA 141-426

BRAVECTO

Fluralaner

Chewable Tablets

Dogs

BRAVECTO kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis), and the treatment and control of tick infestations [Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick)] for 12 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater.

BRAVECTO is also indicated for the treatment and control of Amblyomma americanum (lone star tick) infestations for 8 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater.

Sponsored by:

Intervet, Inc.
Table of Contents

I. GENERAL INFORMATION ....................................................................................... 3

II. EFFECTIVENESS ................................................................................................... 4
   A. Dosage Characterization ................................................................................... 4
   B. Substantial Evidence ....................................................................................... 5

III. TARGET ANIMAL SAFETY ..................................................................................... 35
   A. Margin of Safety Study D009\11-001 ................................................................ 35
   B. Reproductive Safety Study 671596 ................................................................... 36

IV. HUMAN FOOD SAFETY: ....................................................................................... 38

V. USER SAFETY: ................................................................................................... 38

VI. AGENCY CONCLUSIONS: ..................................................................................... 38
   A. Marketing Status: .......................................................................................... 39
   B. Exclusivity: .................................................................................................... 39
   C. Patent Information: ........................................................................................ 39

VII. Appendix 1: Details of Correction ................................................................. 39
I. GENERAL INFORMATION

A. File Number

NADA 141-426

B. Sponsor

Intervet, Inc.
556 Morris Ave.
Summit, NJ 07901

Drug Labeler Code: 000061

C. Proprietary Name

BRAVECTO

D. Established Name

Fluralaner

E. Pharmacological Category

Antiparasitic

F. Dosage Form

Chewable Tablet

G. Amount of Active Ingredient

Each chewable tablet ("chew") contains 112.5, 250, 500, 1000, or 1400 mg fluralaner.

H. How Supplied

BRAVECTO is available in five strengths (112.5, 250, 500, 1000, and 1400 mg fluralaner per chew). Each chew is packaged individually into aluminum foil blister packs sealed with a peelable paper backed foil lid stock. Product may be packaged in 1, 2, or 4 chews per package.

I. Dispensing Status

Rx
J. **Dosage Regimen**

BRAVECTO should be administered orally as a single dose every 12 weeks according to the Dosage Schedule below to provide a minimum dose of 11.4 mg/lb (25 mg/kg) body weight.

BRAVECTO may be administered every 8 weeks in case of potential exposure to *Amblyomma americanum* ticks (see EFFECTIVENESS).

BRAVECTO should be administered with food.

### Dosage Schedule

<table>
<thead>
<tr>
<th>Body Weight Ranges (lb)</th>
<th>Fluralaner Content (mg)</th>
<th>Chews Administered</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4 – 9.9</td>
<td>112.5</td>
<td>One</td>
</tr>
<tr>
<td>&gt;9.9 – 22.0</td>
<td>250</td>
<td>One</td>
</tr>
<tr>
<td>&gt;22.0 – 44.0</td>
<td>500</td>
<td>One</td>
</tr>
<tr>
<td>&gt;44.0 – 88.0</td>
<td>1000</td>
<td>One</td>
</tr>
<tr>
<td>&gt;88.0 – 123.0*</td>
<td>1400</td>
<td>One</td>
</tr>
</tbody>
</table>

*Dogs over 123.0 lb should be administered the appropriate combination of chews

K. **Route of Administration**

Oral

L. **Species/Class**

Dogs

M. **Indications**

BRAVECTO kills adult fleas and is indicated for the treatment and prevention of flea infestations (*Ctenocephalides felis*), and the treatment and control of tick infestations [*Ixodes scapularis* (black-legged tick), *Dermacentor variabilis* (American dog tick), and *Rhipicephalus sanguineus* (brown dog tick)] for 12 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater.

BRAVECTO is also indicated for the treatment and control of *Amblyomma americanum* (lone star tick) infestations for 8 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater.

II. **EFFECTIVENESS**

A. **Dosage Characterization**

1. **Dose Selection**

Various studies conducted with orally and topically administered fluralaner demonstrate a direct relationship between fluralaner dose and duration of effectiveness against fleas and ticks. These studies also indicate that fleas are more susceptible to lower doses of fluralaner than ticks. A 12-week study in
dogs that used a topical formulation of fluralaner at a dose of 10 mg/kg demonstrated 100% effectiveness against fleas versus 51% effectiveness against *Ixodes ricinus* ticks. Pharmacokinetic studies demonstrate that fluralaner has a higher bioavailability when provided by an oral versus topical route of administration. A dose determination study with topical fluralaner at doses ranging from 10 to 40 mg/kg demonstrated that 25 mg/kg provided greater than 90% effectiveness for 12 weeks duration for fleas and *Rhipicephalus sanguineus* ticks. An oral dose of 25 mg/kg was selected for BRAVECTO.

2. Minimum Age

Dose confirmation studies with fluralaner chews demonstrate effectiveness against *Ctenocephalides felis* fleas and *Ixodes scapularis, Dermacentor variabilis*, and *Rhipicephalus sanguineus* ticks for 12 weeks duration in dogs at least 6 months of age when dosed at 25 mg/kg. However, in a European dose confirmation study in young puppies, fluralaner chews were effective against *R. sanguineus* ticks to Day 30 in 8-week-old Beagle puppies that were dosed once at 41-54 mg/kg. In a Japanese dose confirmation study in young puppies, fluralaner chews were effective against *Haemaphysalis longicornis* ticks to Day 58 in 9-week-old puppies that were dosed once at 25 mg/kg. In contrast, fluralaner chews were effective against *H. longicornis* ticks to Day 86 in dogs that were dosed once at 6.5 to 7.5 months of age at 25 mg/kg.

Pharmacokinetic studies demonstrate that fluralaner chews have a substantially lower peak plasma concentration (*C*<sub>max</sub>) and area under the plasma concentration-time curve (AUC), and a shorter plasma elimination half-life (*T*<sub>1/2</sub>), in young puppies (8-9 weeks of age) compared to dogs aged 6 months and older, at approximately the same oral dose.

Therefore, although the margin of safety study supports the safety of BRAVECTO in 8-week old puppies, substantial evidence to support a 12-week duration of effectiveness in dogs less than 6 months of age has not been demonstrated.

**B. Substantial Evidence**

1. For the Treatment and Prevention of Flea Infestations

   a. Laboratory Dose Confirmation Study S11139-03: Effectiveness for Fleas

      (1) Title/Objective
      
      Effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs at the proposed recommended dose against *Ctenocephalides felis* infestations on dogs

      (2) Location and Dates
      
      Young Veterinary Research Services, Turlock CA
      January 12, 2013, to May 16, 2013

      (3) Study Design
(a) Study Animals
20 healthy dogs (pure- and mixed-bred, 6 males and 14 females), 2 to 13.6 years of age, and 7.9 to 29.1 kg body weight

(b) Experimental Design
Prior to allocation to treatment groups on Day -7, an initial flea infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). Dogs were ranked and blocked by live flea count, and one dog from each block was randomly assigned to the untreated control (10 dogs) or the fluralaner (10 dogs) treatment group.

Drug administration was on Day 0. Flea infestations were conducted on Days -2, 28, 56, 84, and 112. At each infestation, each dog was infested with approximately 100 unfed adult fleas.

(c) Drug Administration
On Day 0, the ten dogs in the fluralaner group were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 25.3 to 29.1 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

(d) Measurements and Observations
The primary variable for effectiveness was the counts of live fleas collected from the dogs. At flea counts on Days 2, 30, 58, 86 and 114, fleas were removed and the numbers of live fleas recorded. General health observations were conducted daily and at 1, 3, and 6 hours after drug administration. Dogs were weighed on Day -2. Flea counts and health observations were conducted masked to treatment.

(e) Statistical Methods
A mixed model analysis was used to analyze log-transformed flea counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results
At each flea count, there were a minimum of six dogs in the control group that had an adequate infestation, defined as at least 50 live fleas (50% of the infestations of 100 fleas per dog). On all count days following drug administration, live flea counts between the two groups were significantly different (p ≤ 0.001).
Table 1: Study S11139-00 Effectiveness Against Fleas

<table>
<thead>
<tr>
<th>Day</th>
<th>Control Group Flea Counts</th>
<th>Fluralaner Group Flea Counts</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>74.1</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>30</td>
<td>49.0</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>58</td>
<td>67.4</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>86</td>
<td>69.7</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>114</td>
<td>70.4</td>
<td>0.5</td>
<td>99.3</td>
</tr>
</tbody>
</table>

Flea counts are geometric means and % effectiveness is based on geometric means.

(5) Adverse Reactions
No adverse reactions were reported in this study.

(6) Conclusion
This study demonstrated the effectiveness of fluralaner for the treatment of existing flea infestations for at least 12 weeks when assessed 48 hours after drug administration or infestation.

b. Field Study S11002-00: Effectiveness for Fleas

(1) Title/Objective
Title: Clinical effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs against fleas: a multi-center pivotal field trial

Field Study S11002-00 assessed safety, effectiveness against fleas, signs of flea allergy dermatitis, and palatability.

(2) Investigators and Locations, Study Dates

<table>
<thead>
<tr>
<th>Jay Butan, DVM</th>
<th>Ken McMillan, DVM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lake Worth, FL</td>
<td>Cropwell, AL</td>
</tr>
<tr>
<td>Bill Campagne, DVM</td>
<td>Jason St. Romain, DVM</td>
</tr>
<tr>
<td>Sequin, TX</td>
<td>Zachary, LA</td>
</tr>
<tr>
<td>Beth Carroll, DVM</td>
<td>Joel Sailor, DVM</td>
</tr>
<tr>
<td>Durham, NC</td>
<td>Starke, FL</td>
</tr>
<tr>
<td>Peter Davis, DVM</td>
<td>Roger Sifferman, DVM</td>
</tr>
<tr>
<td>Augusta, ME</td>
<td>Springfield, MO</td>
</tr>
<tr>
<td>Don Dinges, DVM</td>
<td>Troy Smith, DVM</td>
</tr>
<tr>
<td>Leawood, KS</td>
<td>Austin, TX</td>
</tr>
<tr>
<td>Michael Doherty, DVM</td>
<td>David Stanley, DVM</td>
</tr>
<tr>
<td>New Braunfels, TX</td>
<td>Gladstone, MO</td>
</tr>
<tr>
<td>Sam Geller, VMD</td>
<td>John Teeter, DVM</td>
</tr>
<tr>
<td>Quakertown, PA</td>
<td>Shawnee Mission, KS</td>
</tr>
<tr>
<td>Sherwood Gill, DVM</td>
<td>Casey Thomas, DVM</td>
</tr>
<tr>
<td>Lake Charles, LA</td>
<td>Junction City, KS</td>
</tr>
<tr>
<td>Greg Griffeth, DVM</td>
<td>Melissa Wiest, DVM</td>
</tr>
<tr>
<td>Philadelphia, PA</td>
<td>O'Fallon, MO</td>
</tr>
</tbody>
</table>

The study was conducted between August 16, 2011, and June 18, 2012.
(3) Study Design

(a) Study Animals
294 client-owned dogs from 157 households; 224 dogs (118 households) treated with fluralaner chews and 70 dogs (39 households) treated with a combination of spinosad tablets and amitraz collars

Enrollment eligibility included: households with no more than 5 dogs, at least one dog with a minimum of 10 live fleas, and no other pets that could harbor fleas. There were no breed or gender restrictions, but households with pregnant or lactating dogs were not eligible for enrollment. There were restrictions on the use of medications or products with flea treatment or control activity in any household dogs or household premises prior to or during the study period. The study enrolled 153 females and 141 males, 12 weeks to 15 years of age, and 4.4 to 152 lb body weight. The study included purebred and mixed breed dogs.

(b) Experimental Design
Households were randomly assigned to treatment with fluralaner or control in a ratio of three fluralaner households to one control household. Owners treated dogs in the fluralaner group with fluralaner chews once every 12 weeks for three treatments. The fluralaner group finished the study at Visit 8 on Day 182. Owners treated dogs in the active control group with an amitraz collar on study entry and with spinosad tablets once every 4 weeks for three treatments. The control group finished the study at Visit 4 on Day 84. All dogs within a household were in the same treatment group. A primary dog from each household was randomly selected from dogs with 10 or more live fleas at Visit 1. Only the primary dog was assessed for effectiveness against fleas. Owners administered the treatments and they treated all dogs in the household at the same times.

Investigators, who performed flea allergy dermatitis and safety assessments (physical examinations, clinical pathology result assessments, and adverse event assessments), and personnel that performed flea counts were masked to treatment. Treatment administrators at each study location and Owners were not masked.

(c) Drug Administration
In the fluralaner group, Owners administered fluralaner chews, at labeled doses, on Days 0, 84, and 168. Owners recorded palatability at each dosing. In the control group, Owners applied the amitraz collar at the first visit and administered spinosad tablets at labeled doses on Days 0, 28, and 56.

(d) Measurements and Observations
The primary variable was the difference in live flea counts on the primary dogs on Days 28 (Visit 2), 56 (Visit 3), and 84 (Visit 4) versus pretreatment (Visit 1). Additional variables included progression of signs of flea allergy dermatitis, palatability of fluralaner chews,
physical examinations, and clinical pathology. Statistical analyses were not performed for these additional variables.

(e) Statistical Methods
Log-transformed flea counts were analyzed using a mixed model at two-sided 5% significance level. Percent effectiveness against the pretreatment flea counts was calculated based on geometric means.

(4) Results
For each of Visits 2, 3, and 4, the effectiveness of fluralaner, based on geometric means, was greater than 90%.

Table 2: Field Study S11002-00 Effectiveness against Fleas

<table>
<thead>
<tr>
<th>Visit</th>
<th>Fluralaner Group</th>
<th>Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 1 Number of Dogs</td>
<td>117</td>
<td>39</td>
</tr>
<tr>
<td>Visit 1 Geometric Mean Flea Count</td>
<td>32.2</td>
<td>32.6</td>
</tr>
<tr>
<td>Visit 2 Number of Dogs</td>
<td>113</td>
<td>38</td>
</tr>
<tr>
<td>Visit 2 Geometric Mean Flea Count</td>
<td>0.1</td>
<td>1.3</td>
</tr>
<tr>
<td>Visit 2 Percent Effectiveness</td>
<td>99.7%</td>
<td>96.1%</td>
</tr>
<tr>
<td>Visit 3 Number of Dogs</td>
<td>108</td>
<td>34</td>
</tr>
<tr>
<td>Visit 3 Geometric Mean Flea Count</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Visit 3 Percent Effectiveness</td>
<td>99.8%</td>
<td>99.5%</td>
</tr>
<tr>
<td>Visit 3 Number of Dogs</td>
<td>106</td>
<td>32</td>
</tr>
<tr>
<td>Visit 3 Geometric Mean Flea Count</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Visit 3 Percent Effectiveness</td>
<td>99.8%</td>
<td>99.6%</td>
</tr>
</tbody>
</table>

Within each treatment group, geometric mean flea counts were significantly different (p < 0.001) from Visit 1 at Visits 2, 3, and 4.

At least 80% of the dogs with signs attributed to Flea Allergy Dermatitis (FAD) at Visit 1, and not on medications that could affect the assessment of FAD, had resolution of the signs by Visit 4 at Week 12.

Table 3: Field Study S11002-00 Resolution of Signs of Flea Allergy Dermatitis

<table>
<thead>
<tr>
<th>FAD Sign</th>
<th>Percent of Fluralaner Group Dogs with the FAD Sign at Visit 1 that was Resolved at Week 12</th>
<th>Percent of Control Group Dogs with the FAD Sign at Visit 1 that was Resolved at Week 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythema</td>
<td>89% (50/56 dogs)</td>
<td>71% (12/17 dogs)</td>
</tr>
<tr>
<td>Alopecia</td>
<td>88% (30/34 dogs)</td>
<td>80% (8/10 dogs)</td>
</tr>
<tr>
<td>Papules</td>
<td>92% (12/13 dogs)</td>
<td>100% (7/7 dogs)</td>
</tr>
<tr>
<td>Scales</td>
<td>80% (16/20 dogs)</td>
<td>89% (8/9 dogs)</td>
</tr>
<tr>
<td>Crusts</td>
<td>95% (21/22 dogs)</td>
<td>100% (7/7 dogs)</td>
</tr>
<tr>
<td>Excoriation</td>
<td>92% (11/12 dogs)</td>
<td>100% (6/6 dogs)</td>
</tr>
</tbody>
</table>

Dogs with signs of FAD showed improvement in erythema, alopecia, papules, scales, crusts, and excoriation as a direct result of eliminating flea infestations.
Owners recorded palatability information for 559 doses of fluralaner chews administered. Owners first offered fluralaner chews by hand. If not consumed, they offered the chews in food, and if not consumed they placed the chews in the back of dog’s mouths. Dogs voluntarily consumed 80.7% of the doses offered within five minutes of offering.

Table 4: Field Study S11002-00 Palatability of Fluralaner Chews

<table>
<thead>
<tr>
<th>Type of Dose Offering for Assessment of Palatability</th>
<th>Percent of Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Free choice and consumed within 1 minute of offering</td>
<td>74.4%</td>
</tr>
<tr>
<td>Free choice and consumed between 1 and 5 minutes of offering</td>
<td>6.3%</td>
</tr>
<tr>
<td>With food or other treat</td>
<td>12.5%</td>
</tr>
<tr>
<td>Placement in the dog’s mouth (pilling)</td>
<td>5.9%</td>
</tr>
<tr>
<td>Owner unable to dose</td>
<td>0.9%</td>
</tr>
</tbody>
</table>

(5) Adverse Reactions
There were no serious adverse reactions in any of the dogs treated with fluralaner chews or control.

Table 5: Field Study S11002-00 Adverse Reactions

<table>
<thead>
<tr>
<th>Adverse Reaction (AR)</th>
<th>Fluralaner Group: Percent of Dogs with the AR During the 182-Day Study (n=224 dogs)</th>
<th>Control Group: Percent of Dogs with the AR During the 84-Day Study (n=70 dogs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emesis</td>
<td>7.1%</td>
<td>14.3%</td>
</tr>
<tr>
<td>Decreased Appetite</td>
<td>6.7%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4.9%</td>
<td>2.9%</td>
</tr>
<tr>
<td>Lethargy</td>
<td>5.4%</td>
<td>7.1%</td>
</tr>
<tr>
<td>Polydipsia</td>
<td>1.8%</td>
<td>4.3%</td>
</tr>
<tr>
<td>Flatulence</td>
<td>1.3%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

(6) Conclusion
This study demonstrated that fluralaner was safe and effective for the treatment of flea infestations when administered once every 12 weeks to client-owned dogs.

c. Laboratory Dose Confirmation Study S11453-00: Simulated Home Environment for Fleas

(1) Title/Objective
Effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs at their proposed recommended doses for the control of *Ctenocephalides felis* in a simulated home environment for dogs

(2) Location and Dates
Young Veterinary Research Services, Turlock CA
April 17, 2012, to August 21, 2012
(3) Study Design

(a) Study Animals
20 healthy dogs (pure- and mixed-bred, 8 males and 12 females), 0.3 to 10 years of age, and 5.7 to 31.1 kg body weight

(b) Experimental Design
Prior to allocation to treatment groups on Day -32, an initial flea infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). Dogs were ranked and blocked by live flea count, and one dog from each block was randomly assigned to the untreated control (10 dogs) or the fluralaner (10 dogs) treatment group.

Beginning on Day -28, dogs were housed in individual pens that contained a carpet area. To establish a self-perpetuating flea life cycle in each pen, all dogs were infested with approximately 100 newly emerged, unfed adult *C. felis* fleas on Day -28 and again on Day -21. To simulate introductions of new fleas into a home environment, each dog was infested with 50 newly emerged unfed adult fleas on Days 22, 50, and 78.

All live fleas counted on dogs on Day -1 were recovered and recorded but not replaced on the dogs. After the flea counts were completed, the dogs were held overnight in clean pens to prevent re-infestation prior to drug administration on Day 0. Flea counts were performed on all dogs on Day 1 (24 ± 4 hours post-treatment) and on Days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, and 77. Live fleas recovered during these flea counts were re-infested on the dog. The final flea count was on Day 84.

(c) Drug Administration
On Day 0, the ten dogs in the fluralaner group were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 25.1 to 30.9 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

(d) Measurements and Observations
The primary variable for effectiveness was the counts of live fleas collected from the dogs. Flea counts were conducted on all dogs on Days -1, 1, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, and 84. General health observations were conducted daily and at 1, 3, and 6 hours after drug administration. Dogs were weighed on Days -1, 28, and 56. Flea counts and health observations were conducted masked to treatment.

(e) Statistical Methods
A mixed model analysis was used to analyze log-transformed flea counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.
(4) Results

On Day -1, the geometric mean flea counts on control and fluralaner group dogs were 26.4 and 14.1, respectively. The Day -1 live flea counts were not significantly different (p = 0.419) between the two groups. On all count days following drug administration, live flea counts between the two groups were significantly different (p ≤ 0.021).

Table 6: Simulated Home Environment S11453-00 Effectiveness

<table>
<thead>
<tr>
<th>Day</th>
<th>Control Group Flea Counts a</th>
<th>Fluralaner Group Flea Counts a</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>-1</td>
<td>26.4</td>
<td>14.1</td>
<td>Not applicable</td>
</tr>
<tr>
<td>1</td>
<td>6.0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>7</td>
<td>1.8</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>14</td>
<td>2.7</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>21</td>
<td>4.1</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>28</td>
<td>24.8</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>35</td>
<td>15.7</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>42</td>
<td>10.8</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>49</td>
<td>20.6</td>
<td>0.1</td>
<td>99.7</td>
</tr>
<tr>
<td>56</td>
<td>40.6</td>
<td>0.1</td>
<td>99.8</td>
</tr>
<tr>
<td>63</td>
<td>25.6</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>70</td>
<td>16.2</td>
<td>0.1</td>
<td>99.6</td>
</tr>
<tr>
<td>77</td>
<td>12.3</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>84</td>
<td>33.2</td>
<td>0</td>
<td>100</td>
</tr>
</tbody>
</table>

a Flea counts are geometric means and % effectiveness is based on geometric means.

(5) Adverse Reactions

No adverse reactions were reported in this study.

(6) Conclusion

This study demonstrated that fluralaner was effective for the prevention of flea infestations on dogs in a simulated home environment for 12 weeks.

d. Laboratory Dose Confirmation Study S12142-00: Onset of Activity for Fleas

(1) Title/Objective

Determination of the onset of activity of fluralaner against fleas (Ctenocephalides felis) on dogs 0.5, 1, or 2 hours after oral treatment with fluralaner at a dose of 25 mg/kg body weight

(2) Location and Dates

ClinVet International Pty Ltd., Bloemfontein, South Africa
September 18, 2012, to September 25, 2012

(3) Study Design
(a) Study Animals
36 healthy dogs (Beagles and mongrels, 18 males and 18 females), 9 months to 10 years of age, and 9.4 to 18.8 kg body weight

(b) Experimental Design
Prior to allocation to treatment groups on Day -2, an initial flea infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). Dogs were ranked and blocked by live flea count, and one dog from each block was randomly assigned to untreated control (6 dogs) or fluralaner (6 dogs) subgroup. The control and fluralaner groups each had three subgroups for flea count times at 0.5, 1, and 2 hours after drug administration.

Drug administration was on Day 0. On Day -1, each dog was infested with approximately 100 unfed adult fleas.

(c) Drug Administration
On Day 0, the 18 dogs in the fluralaner group were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 25.2 to 35.8 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

(d) Measurements and Observations
The primary variable for effectiveness was the count of live fleas collected from the dogs. Flea counts were performed at 0.5, 1, and 2 hours after drug administration on Day 0. General health observations were conducted daily. Dogs were weighed and examined on Day -2. Flea counts and health observations were conducted masked to treatment.

(e) Statistical Methods
A mixed model analysis was used to analyze log-transformed flea counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results
At each flea count, the six dogs in the control subgroups each had an adequate infestation, defined as at least 50 live fleas (50% of the infestations of 100 fleas per dog).

At two hours after drug administration, the live flea count in the fluralaner group was significantly different from the control group (p = 0.0046).
Table 7: Onset of Activity S12142-00 Live Flea Count Effectiveness

<table>
<thead>
<tr>
<th>Time of Flea Count after Dosing</th>
<th>Control Group Flea Counts a</th>
<th>Fluralaner Group Flea Counts a</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5 hours</td>
<td>74.0</td>
<td>78.7</td>
<td>0.0</td>
</tr>
<tr>
<td>1 hour</td>
<td>84.9</td>
<td>78.1</td>
<td>8.0</td>
</tr>
<tr>
<td>2 hours</td>
<td>77.0</td>
<td>48.7</td>
<td>36.7</td>
</tr>
</tbody>
</table>

a Flea counts are geometric means and % effectiveness is based on geometric means.

(5) Adverse Reactions
No adverse reactions were reported in this study.

(6) Conclusion
This study demonstrated that the onset of activity against *C. felis* fleas was observed two hours following administration of fluralaner, resulting in a 36.7% reduction in live fleas at that time point.

2. Speed of Kill for Fleas and Ticks
   a. Laboratory Dose Confirmation Study S11261-00: Speed of Kill for Fleas and Ticks

   (1) Title/Objective
   Determination of the speed of kill of fluralaner administered once orally at a dose of 25 mg/kg body weight against tick infestations (*Ixodes ricinus*) and flea infestations (*Ctenocephalides felis*) on dogs

   (2) Location and Dates

   (3) Study Design
   (a) Study Animals
   12 healthy dogs (Beagles, 10 males and 2 females), 7 months to 6 years of age, and 9.0 to 16.6 kg body weight
   (b) Experimental Design
   Prior to allocation to treatment groups on Day -5, an initial flea infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). Dogs were ranked and blocked by live flea count, and one dog from each block was randomly assigned to the untreated control (6 dogs) or the fluralaner (6 dogs) treatment group.

   Drug administration was on Day 0. Flea and tick co-infestations were conducted on Days -2, 28, 56, 84, and 111. At each infestation, each dog was infested with approximately 80 unfed adult fleas and approximately 50 female and 10 male unfed adult *I. ricinus* ticks.
Flea and tick counts were performed on Day 1, 12 hours after drug administration, and on Days 29, 57, 85, and 112, 12 hours after flea and tick infestations. Fleas and ticks were not returned to the dog after counting.

(c) Drug Administration
On Day 0, the six dogs in the fluralaner group were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 25.7 to 33.9 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

(d) Measurements and Observations
The primary variables for effectiveness were the counts of live fleas and ticks collected from the dogs. At flea and tick counts on Days 1, 29, 57, 85 and 112, fleas and ticks were removed and the numbers of live and dead fleas and ticks were recorded. General health observations were conducted daily. Dogs were weighed on Day -1. Flea and tick counts and health observations were conducted masked to treatment.

(e) Statistical Methods
A mixed model analysis was used to analyze log-transformed flea and tick counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results
At each flea count, the six dogs in the control group each had an adequate infestation, defined as at least 40 live fleas (50% of the infestations of 80 fleas per dog). At each tick count, the six dogs in the control group each had an adequate infestation, defined as at least 15 live ticks (25% of the infestations of 60 ticks per dog).

The fluralaner group had greater than 90% reduction in live flea counts at 12 hours following infestation for 16 weeks (infestation on Day 111) and greater than 90% reduction in live tick counts at 12 hours following infestation for 12 weeks (infestation on Day 84).

On all count days following drug administration, live flea and tick counts for the fluralaner group were significantly different from the control group (p < 0.001).
Table 8: Speed of Kill S11261-00 Live Flea Count Effectiveness

<table>
<thead>
<tr>
<th>Day for 12-hour counts</th>
<th>Control Group Flea Counts a</th>
<th>Fluralaner Group Flea Counts a</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>73.6</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>29</td>
<td>73.5</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>57</td>
<td>89.6</td>
<td>0.1</td>
<td>99.8</td>
</tr>
<tr>
<td>85</td>
<td>76.4</td>
<td>1.0</td>
<td>98.7</td>
</tr>
<tr>
<td>112</td>
<td>71.9</td>
<td>5.4</td>
<td>92.5</td>
</tr>
</tbody>
</table>

a Flea counts are geometric means and % effectiveness is based on geometric means.

Table 9: Speed of Kill S11261-00 Live Tick Count Effectiveness

<table>
<thead>
<tr>
<th>Day for 12-hour counts</th>
<th>Control Group Tick Counts a</th>
<th>Fluralaner Group Tick Counts a</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>28.1</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>29</td>
<td>36.8</td>
<td>0.1</td>
<td>99.7</td>
</tr>
<tr>
<td>57</td>
<td>32.0</td>
<td>0.3</td>
<td>99.2</td>
</tr>
<tr>
<td>85</td>
<td>34.3</td>
<td>0.6</td>
<td>98.3</td>
</tr>
<tr>
<td>112</td>
<td>35.2</td>
<td>10.4</td>
<td>70.5</td>
</tr>
</tbody>
</table>

a Tick counts are geometric means and % effectiveness is based on geometric means.

Of the total number of fleas and ticks applied to the dogs in each group on each infestation day, smaller percentages of fleas and ticks were recovered (live or dead) during flea and tick counts in the fluralaner group compared to the control group.

In the control group dogs, 88% to 96% of the infested fleas were recovered compared with 19% to 40% of the infested fleas that were recovered from fluralaner group dogs.

In the control group dogs, 55% to 65% of the infested ticks were recovered compared with 46% to 59% of the infested ticks that were recovered from fluralaner group dogs.

The following table reports the flea and tick mortality, which is the percentage of the recovered fleas and ticks that were found dead at each flea and tick count.

Table 10: Speed of Kill S11261-00 Flea and Tick Mortality

<table>
<thead>
<tr>
<th>Day for 12-hour counts</th>
<th>Control Group % Flea Mortality</th>
<th>Fluralaner Group % Flea Mortality</th>
<th>Control Group % Tick Mortality</th>
<th>Fluralaner Group % Tick Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.9</td>
<td>100</td>
<td>12.7</td>
<td>100</td>
</tr>
<tr>
<td>29</td>
<td>0.0</td>
<td>100</td>
<td>5.1</td>
<td>99.5</td>
</tr>
<tr>
<td>57</td>
<td>0.2</td>
<td>98.9</td>
<td>15.0</td>
<td>99.0</td>
</tr>
<tr>
<td>85</td>
<td>0.0</td>
<td>87.8</td>
<td>10.3</td>
<td>96.7</td>
</tr>
<tr>
<td>112</td>
<td>0.2</td>
<td>53.6</td>
<td>7.0</td>
<td>63.8</td>
</tr>
</tbody>
</table>

(5) Adverse Reactions

No adverse reactions were reported in this study.
(6) Conclusion
This study demonstrated that fluralaner killed *C. felis* fleas and *I. ricinus* ticks and reduced the numbers of live *C. felis* fleas and *I. ricinus* ticks on dogs by greater than 98% within 12 hours after treatment or infestation for 12 weeks.

3. For the Treatment and Control of Tick Infestations
   a. Laboratory Dose Confirmation Study S11115-02: *Ixodes scapularis* Ticks

   (1) Title/Objective
   Effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs at their proposed recommended dose against *Ixodes scapularis* infestations in dogs

   (2) Location and Dates
   Young Veterinary Research Services, Turlock CA
   August 19, 2011, to December 21, 2011

   (3) Study Design
   (a) Study Animals
   20 healthy dogs (mostly mixed breed; 5 males and 15 females), 3.5 to 14.9 years of age, and 8.5 to 30.7 kg body weight

   (b) Experimental Design
   Prior to allocation to treatment groups on Day -3, an initial tick infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). Dogs were ranked and blocked by live tick count, and one dog from each block was randomly assigned to the untreated control (10 dogs) or the fluralaner (10 dogs) treatment group.

   Drug administration was on Day 0. Tick infestations were conducted on Days -2, 28, 56, 84, and 112. At each infestation, each dog was infested with approximately 75 adult, newly emerged, unfed *I. scapularis* ticks (approximate 50:50 ratio of male to female ticks).

   (c) Drug Administration
   On Day 0, the ten dogs in the fluralaner group were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 25.0 to 29.3 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

   (d) Measurements and Observations
   The primary variables for effectiveness were the counts of live ticks collected from the dogs. At tick counts on Days 2, 30, 58, 86 and 114, ticks were removed and the numbers of live and dead ticks were
recorded. General health observations were conducted daily and at 1, 3, and 6 hours after drug administration. Dogs were weighed on Day -1. Tick counts and health observations were conducted masked to treatment.

(e) Statistical Methods
A mixed model analysis was used to analyze log-transformed tick counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results
At each tick count day, at least 8 of the 10 dogs in the control group each had an adequate infestation, defined as at least 19 live *I. scapularis* ticks (25% of the infestations of 75 ticks per dog).

The fluralaner group had greater than 90% reduction in live tick counts at 48 hours following treatment or infestation for 12 weeks (infestation on Day 84).

On all count days following drug administration, live tick counts for the fluralaner group were significantly different from the control group (p < 0.001).

Table 11: *I. scapularis* S11115-02 Live Tick Count Effectiveness

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Live Tick Counts a</th>
<th>Fluralaner Group Live Tick Counts a</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>42.6</td>
<td>0.5</td>
<td>98.9</td>
</tr>
<tr>
<td>30</td>
<td>43.2</td>
<td>1.0</td>
<td>97.7</td>
</tr>
<tr>
<td>58</td>
<td>39.0</td>
<td>0.2</td>
<td>99.4</td>
</tr>
<tr>
<td>86</td>
<td>34.0</td>
<td>1.2</td>
<td>96.6</td>
</tr>
<tr>
<td>114</td>
<td>32.7</td>
<td>3.4</td>
<td>89.6</td>
</tr>
</tbody>
</table>

a Tick counts are geometric means and % effectiveness is based on geometric means.

On all count days following drug administration, dead tick counts for the fluralaner group were significantly different from the control group (p < 0.001).

Table 12: *I. scapularis* S11115-02 Dead Tick Count Results

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Dead Tick Counts a</th>
<th>Fluralaner Group Dead Tick Counts a</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>0.6</td>
<td>8.7</td>
</tr>
<tr>
<td>30</td>
<td>0.3</td>
<td>12.2</td>
</tr>
<tr>
<td>58</td>
<td>0.0</td>
<td>12.7</td>
</tr>
<tr>
<td>86</td>
<td>0.1</td>
<td>10.4</td>
</tr>
<tr>
<td>114</td>
<td>0.0</td>
<td>12.5</td>
</tr>
</tbody>
</table>

a Tick counts are geometric means

(5) Adverse Reactions
No adverse reactions were reported in this study.
(6) Conclusion
This study demonstrated the effectiveness of fluralaner for the control (reduced live ticks) and treatment (increased dead ticks) of *I. scapularis* ticks for 12 weeks when assessed at 48 hours after drug administration or infestation.

b. Laboratory Dose Confirmation Study S11115-03: *Ixodes scapularis* Ticks

(1) Title/Objective
Effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs at the proposed recommended dose against *Ixodes scapularis* infestations in dogs

(2) Location and Dates
BerTek, Inc., Greenbrier, AR
February 3, 2013, to May 10, 2013

(3) Study Design

(a) Study Animals
20 healthy dogs (pure- and mixed-bred; 10 males and 10 females), 0.5 to 10.0 years of age, and 5.8 to 21.7 kg body weight

(b) Experimental Design
Prior to allocation to treatment groups on Day -5, an initial tick infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). Dogs were ranked and blocked by live tick count, and one dog from each block was randomly assigned to the untreated control (10 dogs) or the fluralaner (10 dogs) treatment group.

Drug administration was on Day 0. Tick infestations were conducted on Days -2, 28, 56, and 84. At each infestation, each dog was infested with approximately 75 adult, newly emerged, unfed *I. scapularis* ticks (approximate 50:50 ratio of male to female ticks).

(c) Drug Administration
On Day 0, the ten dogs in the fluralaner group were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 25.9 to 35.9 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

(d) Measurements and Observations
The primary variables for effectiveness were the counts of live ticks collected from the dogs. At tick counts on Days 2, 30, 58, and 86, ticks were removed and the numbers of live and dead ticks were recorded. General health observations were conducted daily and at 1, 3, and 6 hours after drug administration. Dogs were weighed on Day
-1. Tick counts and health observations were conducted masked to treatment.

(e) Statistical Methods
A mixed model analysis was used to analyze log-transformed tick counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results
At each tick count day, at least 9 of the 10 dogs in the control group each had an adequate infestation, defined as at least 19 live *I. scapularis* ticks (25% of the infestations of 75 ticks per dog).

The fluralaner group had greater than 90% reduction in live tick counts at 48 hours following treatment or infestation for 12 weeks (infestation on Day 84).

On all count days following drug administration, live tick counts for the fluralaner group were significantly different from the control group (p < 0.001).

Table 13: *I. scapularis* S11115-03 Live Tick Count Effectiveness

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Live Tick Counts</th>
<th>Fluralaner Group Live Tick Counts</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>35.3</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>30</td>
<td>38.3</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>58</td>
<td>43.8</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>86</td>
<td>36.6</td>
<td>0.9</td>
<td>97.6</td>
</tr>
</tbody>
</table>

* Tick counts are geometric means and % effectiveness is based on geometric means.

On all count days following drug administration, dead tick counts for the fluralaner group were significantly different from the control group (p < 0.001).

Table 14: *I. scapularis* S11115-03 Dead Tick Count Results

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Dead Tick Counts</th>
<th>Fluralaner Group Dead Counts</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>0.5</td>
<td>9.5</td>
</tr>
<tr>
<td>30</td>
<td>0.0</td>
<td>15.7</td>
</tr>
<tr>
<td>58</td>
<td>0.0</td>
<td>12.6</td>
</tr>
<tr>
<td>86</td>
<td>0.0</td>
<td>7.9</td>
</tr>
</tbody>
</table>

* Tick counts are geometric means.

(5) Adverse Reactions
No adverse reactions were reported in this study.

(6) Conclusion
This study demonstrated the effectiveness of fluralaner for the control (reduced live ticks) and treatment (increased dead ticks) of *I. scapularis*
ticks for 12 weeks when assessed at 48 hours after drug administration or infestation.

c. Laboratory Dose Confirmation Study S12372-01: *Dermacentor variabilis* Ticks

(1) Title/Objective

Effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs at the proposed recommended dose against *Dermacentor variabilis* infestations on dogs using two different tick infestation schedules

(2) Location and Dates

BerTek, Inc., Greenbrier, AR
January 5, 2013, to April 11, 2013

(3) Study Design

(a) Study Animals

36 healthy dogs (pure- and mixed-bred; 25 males and 11 females), 0.6 to 7.0 years of age, and 5.4 to 15.1 kg body weight

(b) Experimental Design

Prior to allocation to treatment groups on Day -3, an initial tick infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). There were two infestations schedules used in this study (Days -2, 28 and 56; and Day 86 only) with an untreated control and a fluralaner treatment group within each schedule. Dogs were ranked and blocked by live tick count, and one dog from each block was randomly assigned to one of four groups (9 dogs per group).

Drug administration was on Day 0. Tick infestations were conducted on one fluralaner and one control group of dogs on Days -2, 28 and 56 and only on Day 84 for the remaining fluralaner and control groups. At each infestation, each dog was infested with approximately 50 adult, unfed *D. variabilis* ticks (approximate 50:50 ratio of male to female ticks).

(c) Drug Administration

On Day 0, the nine dogs in each of the fluralaner groups were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 27.4.0 to 41.7 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

(d) Measurements and Observations

The primary variables for effectiveness were the counts of live ticks collected from the dogs. At tick counts on Days 2, 30, 58, and 86, ticks were removed and the numbers of live and dead ticks were recorded. General health observations were conducted daily and at 1, 3, and 6 hours after drug administration. Dogs were weighed on Day
-1. Tick counts and health observations were conducted masked to treatment.

(e) Statistical Methods

A mixed model analysis was used to analyze log-transformed tick counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results

At each tick count day, at least 8 of the 9 dogs both control groups had an adequate infestation, defined as at least 13 live *D. variabilis* ticks (25% of the infestations of 50 ticks per dog).

The fluralaner group had greater than 90% reduction in live tick counts at 48 hours following treatment or infestation for 12 weeks (infestation on Day 84).

On all count days following drug administration, live tick counts for the fluralaner group were significantly different from the control group (*p < 0.001*).

Table 15: *D. variabilis* S12372-01 Live Tick Count Effectiveness

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Live Tick Counts(a)</th>
<th>Fluralaner Group Live Tick Counts(a)</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>34.6</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>30</td>
<td>27.2</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>58</td>
<td>23.6</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>86</td>
<td>17.3</td>
<td>0.2</td>
<td>98.7</td>
</tr>
</tbody>
</table>

\(a\) Tick counts are geometric means and % effectiveness is based on geometric means.

On all count days following drug administration, dead tick counts for the fluralaner group were significantly different from the control group (*p < 0.001*).

Table 16: *D. variabilis* S12372-01 Dead Tick Count Results

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Dead Tick Counts(a)</th>
<th>Fluralaner Group Dead Tick Counts(a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>0.1</td>
<td>16.4</td>
</tr>
<tr>
<td>30</td>
<td>0.1</td>
<td>5.6</td>
</tr>
<tr>
<td>58</td>
<td>0.2</td>
<td>5.1</td>
</tr>
<tr>
<td>86</td>
<td>0.1</td>
<td>6.3</td>
</tr>
</tbody>
</table>

\(a\) Tick counts are geometric means.

(5) Adverse Reactions

No adverse reactions were reported in this study.

(6) Conclusion

This study demonstrated the effectiveness of fluralaner for the control (reduced live ticks) and treatment (increased dead ticks) of *D. variabilis*...
ticks for 12 weeks when assessed at 48 hours after drug administration or infestation.

d. Laboratory Dose Confirmation Study S12372-02: *Dermacentor variabilis* Ticks

(1) Title/Objective
Effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs at the proposed recommended dose against *Dermacentor variabilis* infestations on dogs using two different tick infestation schedules

(2) Location and Dates
Cheri-Hill Kennel & Supply, Inc., Stanwood, MI

(3) Study Design

(a) Study Animals
40 healthy dogs (Beagles; 20 males and 20 females), 1.3 to 2.0 years of age, and 7.7 to 19.4 kg body weight

(b) Experimental Design
Prior to allocation to treatment groups on Day -5, an initial tick infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). There were two infestations schedules used in this study (Days -2, 28 and 56; and Day 86 only) with an untreated control and a fluralaner treatment group within each schedule. Dogs were ranked and blocked by live tick count, and one dog from each block was randomly assigned to one of four groups (10 dogs per group).

Drug administration was on Day 0. Tick infestations were conducted on one fluralaner and one control group of dogs on Days -2, 28 and 56 and only on Day 84 for the remaining fluralaner and control groups. At each infestation, each dog was infested with approximately 50 adult, unfed *D. variabilis* ticks (approximate 50:50 ratio of male to female ticks).

(c) Drug Administration
On Day 0, the ten dogs in each of the fluralaner groups were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 25.5 to 35.2 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

(d) Measurements and Observations
The primary variables for effectiveness were the counts of live ticks collected from the dogs. At tick counts on Days 2, 30, 58, and 86, ticks were removed and the numbers of live and dead ticks were recorded. General health observations were conducted daily and at 1, 3, and 6 hours after drug administration. Dogs were weighed on Day
-2. Tick counts and health observations were conducted masked to treatment.

(e) Statistical Methods
A mixed model analysis was used to analyze log-transformed tick counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results
At each tick count day, all 10 dogs in both control groups had an adequate infestation, defined as at least 13 live *D. variabilis* ticks (25% of the infestations of 50 ticks per dog).

The fluralaner group had greater than 90% reduction in live tick counts at 48 hours following treatment or infestation for 12 weeks (infestation on Day 84).

On all count days following drug administration, live tick counts for the fluralaner group were significantly different from the control group (p < 0.001).

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Live Tick Counts(a)</th>
<th>Fluralaner Group Live Tick Counts(a)</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>38.3</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>30</td>
<td>29.0</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>58</td>
<td>31.7</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>86</td>
<td>30.7</td>
<td>0.3</td>
<td>99.0</td>
</tr>
</tbody>
</table>

\(a\) Tick counts are geometric means and % effectiveness is based on geometric means.

On all count days following drug administration, dead tick counts for the fluralaner group were significantly different from the control group (p < 0.001).

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Dead Tick Counts(a)</th>
<th>Fluralaner Group Dead Counts(a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>0.1</td>
<td>25.0</td>
</tr>
<tr>
<td>30</td>
<td>0.1</td>
<td>22.5</td>
</tr>
<tr>
<td>58</td>
<td>0.1</td>
<td>12.6</td>
</tr>
<tr>
<td>86</td>
<td>0.1</td>
<td>17.2</td>
</tr>
</tbody>
</table>

\(a\) Tick counts are geometric means.

(5) Adverse Reactions
No adverse reactions were reported in this study.

(6) Conclusion
This study demonstrated the effectiveness of fluralaner for the control (reduced live ticks) and treatment (increased dead ticks) of *D. variabilis*.
ticks for 12 weeks when assessed at 48 hours after drug administration or infestation.

e. Laboratory Dose Confirmation Study S11172-02: *Rhipicephalus sanguineus* Ticks

(1) Title/Objective

Effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs at their proposed recommended dose against *Rhipicephalus sanguineus* infestations in dogs

(2) Location and Dates

BerTek, Inc., Greenbrier, AR
October 16, 2011, to February 17, 2012

(3) Study Design

(a) Study Animals

20 healthy dogs (mostly mixed breed; 13 males and 7 females), 2.4 to 11.3 years of age, and 7.5 to 14.9 kg body weight

(b) Experimental Design

Prior to allocation to treatment groups on Day -5, an initial tick infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). Dogs were ranked and blocked by live tick count, and one dog from each block was randomly assigned to the untreated control (10 dogs) or the fluralaner (10 dogs) treatment group.

Drug administration was on Day 0. Tick infestations were conducted on Days -2, 28, 56, 84, and 112. At each infestation, each dog was infested with approximately 50 adult, unfed *R. sanguineus* ticks.

(c) Drug Administration

On Day 0, the ten dogs in the fluralaner group were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 25.2 to 33.9 mg/kg per dog. The chews were administered by placing them on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

(d) Measurements and Observations

The primary variables for effectiveness were the counts of live ticks collected from the dogs. At tick counts on Days 2, 30, 58, 86 and 114, ticks were removed and the numbers of live and dead ticks were recorded. General health observations were conducted daily and at 1, 3, and 6 hours after drug administration. Dogs were weighed on Day -2. Tick counts and health observations were conducted masked to treatment.
(e) Statistical Methods
A mixed model analysis was used to analyze log-transformed tick counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results
At each tick count day, at least 8 of the 10 dogs in the control group each had an adequate infestation, defined as at least 13 live *R. sanguineus* ticks (25% of the infestations of 50 ticks per dog).

The fluralaner group had greater than 90% reduction in live tick counts at 48 hours following treatment or infestation for 12 weeks (infestation on Day 84).

On all count days following drug administration except Day 114, live tick counts for the fluralaner group were significantly different from the control group (p < 0.001).

Table 19: *R. sanguineus* S11172-02 Live Tick Count Effectiveness

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Live Tick Counts <em>a</em></th>
<th>Fluralaner Group Live Tick Counts <em>a</em></th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>37.4</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>30</td>
<td>26.1</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>58</td>
<td>18.1</td>
<td>0.1</td>
<td>99.6</td>
</tr>
<tr>
<td>86</td>
<td>19.4</td>
<td>1.2</td>
<td>93.9</td>
</tr>
<tr>
<td>114</td>
<td>18.8</td>
<td>9.2</td>
<td>51.0</td>
</tr>
</tbody>
</table>

* *a* Tick counts are geometric means and % effectiveness is based on geometric means.

On all count days following drug administration, dead tick counts for the fluralaner group were significantly different from the control group (p < 0.05).

Table 20: *R. sanguineus* S11172-02 Dead Tick Count Results

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Dead Tick Counts <em>a</em></th>
<th>Fluralaner Group Dead Tick Counts <em>a</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>0.1</td>
<td>4.6</td>
</tr>
<tr>
<td>30</td>
<td>0.6</td>
<td>5.4</td>
</tr>
<tr>
<td>58</td>
<td>1.3</td>
<td>4.0</td>
</tr>
<tr>
<td>86</td>
<td>0.4</td>
<td>6.7</td>
</tr>
<tr>
<td>114</td>
<td>0.0</td>
<td>1.2</td>
</tr>
</tbody>
</table>

* *a* Tick counts are geometric means.

(5) Adverse Reactions
No adverse reactions were reported in this study.

(6) Conclusion
This study demonstrated the effectiveness of fluralaner for the control (reduced live ticks) and treatment (increased dead ticks) of *R. sanguineus*
ticks for 12 weeks when assessed at 48 hours after drug administration or infestation.

f. Laboratory Dose Confirmation Study S11172-03: *Rhipicephalus sanguineus* Ticks

(1) Title/Objective
Effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs at their proposed recommended dose against *Rhipicephalus sanguineus* infestations in dogs

(2) Location and Dates
Young Veterinary Research Services, Turlock CA
November 18, 2011, to February 27, 2012

(3) Study Design
(a) Study Animals
20 healthy dogs (Beagles, 11 males and 9 females), 5.5 to 6.6 years of age, and 7.7 to 13.7 kg body weight

(b) Experimental Design
Prior to allocation to treatment groups on Day -3, an initial tick infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). Dogs were ranked and blocked by live tick count, and one dog from each block was randomly assigned to the untreated control (10 dogs) or the fluralaner (10 dogs) treatment group.

Drug administration was on Day 0. Tick infestations were conducted on Days -2, 28, 56, and 84. At each infestation, each dog was infested with approximately 50 adult, unfed *R. sanguineus* ticks.

(c) Drug Administration
On Day 0, the ten dogs in the fluralaner group were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 25.7 to 32.2 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

(d) Measurements and Observations
The primary variables for effectiveness were the counts of live ticks collected from the dogs. At tick counts on Days 2, 30, 58, and 86, ticks were removed and the numbers of live and dead ticks were recorded. General health observations were conducted daily and at 1, 3, and 6 hours after drug administration. Dogs were weighed on Day -2. Tick counts and health observations were conducted masked to treatment.
(e) Statistical Methods
A mixed model analysis was used to analyze log-transformed tick counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results
At each tick count day, at least 9 of the 10 dogs in the control group each had an adequate infestation, defined as at least 13 live *R. sanguineus* ticks (25% of the infestations of 50 ticks per dog).

The fluralaner group had greater than 90% reduction in live tick counts at 48 hours following treatment or infestation for 8 weeks (infestation on Day 56).

On all count days following drug administration, live tick counts for the fluralaner group were significantly different from the control group (\( p \leq 0.001 \)).

Table 21: *R. sanguineus* S11172-03 Live Tick Count Effectiveness

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Live Tick Counts</th>
<th>Fluralaner Group Live Tick Counts</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>21.1</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>30</td>
<td>26.4</td>
<td>0.3</td>
<td>98.9</td>
</tr>
<tr>
<td>58</td>
<td>28.8</td>
<td>0.4</td>
<td>98.6</td>
</tr>
<tr>
<td>86</td>
<td>22.3</td>
<td>2.8</td>
<td>87.6</td>
</tr>
</tbody>
</table>

*Tick counts are geometric means and % effectiveness is based on geometric means.*

On all count days following drug administration, dead tick counts for the fluralaner group were significantly different from the control group (\( p < 0.001 \)).

Table 22: *R. sanguineus* S11172-03 Dead Tick Count Results

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Dead Tick Counts</th>
<th>Fluralaner Group Dead Tick Counts</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>0.0</td>
<td>1.3</td>
</tr>
<tr>
<td>30</td>
<td>0.0</td>
<td>2.6</td>
</tr>
<tr>
<td>58</td>
<td>0.0</td>
<td>5.0</td>
</tr>
<tr>
<td>86</td>
<td>0.0</td>
<td>3.6</td>
</tr>
</tbody>
</table>

*Tick counts are geometric means.*

(5) Adverse Reactions
One dog developed edema and hyperemia of the upper lips within one hour of fluralaner chew administration. The edema improved without intervention over the next six hours and the dog was normal the next day.

(6) Conclusion
This study demonstrated the effectiveness of fluralaner for the control (reduced live ticks) and treatment (increased dead ticks) of *R. sanguineus* ticks for 8 weeks when assessed at 48 hours after drug administration or
infestation. Fluralaner failed to demonstrate adequate effectiveness (<90%) for the control of *R. sanguineus* for 12 weeks when assessed at 48 hours after drug administration or infestation. One dog had a mild, self-limiting allergic reaction (edema and hyperemia of upper lips) to fluralaner chews.

g. Laboratory Dose Confirmation Study S11172-04: *Rhipicephalus sanguineus* Ticks

(1) Title/Objective
Effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs at their proposed recommended dose against *Rhipicephalus sanguineus* infestations in dogs

(2) Location and Dates
MPI Research, Mattawan, MI
February 24, 2013, to June 1, 2013

(3) Study Design
(a) Study Animals
20 healthy dogs (Beagles, 10 males and 10 females), approximately 0.5 years of age, and 4.3 to 8.7 kg body weight

(b) Experimental Design
Prior to allocation to treatment groups on Day -6, an initial tick infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). Dogs were ranked and blocked by live tick count, and one dog from each block was randomly assigned to the untreated control (10 dogs) or the fluralaner (10 dogs) treatment group.

Drug administration was on Day 0. Tick infestations were conducted on Days -2, 28, 56, and 84. At each infestation, each dog was infested with approximately 50 adult, unfed (approximate 50:50 ratio of male to female ticks) *R. sanguineus* ticks.

(c) Drug Administration
On Day 0, the ten dogs in the fluralaner group were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 26.0 to 40.0 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

(d) Measurements and Observations
The primary variables for effectiveness were the counts of live ticks collected from the dogs. At tick counts on Days 2, 30, 58, and 86, ticks were removed and the numbers of live and dead ticks were recorded. General health observations were conducted daily and at 1, 3, and 6 hours after drug administration. Dogs were weighed on Day
-2. Tick counts and health observations were conducted masked to treatment.

(e) Statistical Methods
A mixed model analysis was used to analyze log-transformed tick counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results
At each tick count day, at least 8 of the 10 dogs in the control group each had an adequate infestation, defined as at least 13 live \( R. \ sanguineus \) ticks (25% of the infestations of 50 ticks per dog).

The fluralaner group had greater than 90% reduction in live tick counts at 48 hours following treatment or infestation for 12 weeks (infestation on Day 84).

On all count days following drug administration, live tick counts for the fluralaner group were significantly different from the control group (\( p < 0.001 \)).

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Live Tick Counts(^a)</th>
<th>Fluralaner Group Live Tick Counts(^a)</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>30.4</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>30</td>
<td>24.0</td>
<td>0.0</td>
<td>100</td>
</tr>
<tr>
<td>58</td>
<td>17.6</td>
<td>0.1</td>
<td>99.6</td>
</tr>
<tr>
<td>86</td>
<td>17.8</td>
<td>0.5</td>
<td>97.4</td>
</tr>
</tbody>
</table>
\(^a\) Tick counts are geometric means and % effectiveness is based on geometric means.

On count Days 2 and 30 following drug administration, dead tick counts for the fluralaner group were significantly different from the control group (\( p < 0.002 \)).

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Dead Tick Counts(^a)</th>
<th>Fluralaner Group Dead Tick Counts(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>0.6</td>
<td>3.5</td>
</tr>
<tr>
<td>30</td>
<td>0.0</td>
<td>2.0</td>
</tr>
<tr>
<td>58</td>
<td>0.1</td>
<td>0.3</td>
</tr>
<tr>
<td>86</td>
<td>0.1</td>
<td>0.1</td>
</tr>
</tbody>
</table>
\(^a\) Tick counts are geometric means.

(5) Adverse Reactions
No adverse reactions were reported in this study.

(6) Conclusion
This study demonstrated the effectiveness of fluralaner for the control (reduced live ticks) and treatment (increased dead ticks) of \( R. \ sanguineus \)
ticks for 12 weeks when assessed at 48 hours after drug administration or infestation.

**Overall Conclusion for *R. sanguineus***:
Although Study S11172-03 failed to demonstrate > 90% effectiveness at Day 86, when combined with Study S11172-02 and Study S11172-04, the average effectiveness at Day 86 is > 90% (93.0%). Therefore, the combined data demonstrates that fluralaner is effective for the treatment and control of *R. sanguineus* infestations for 12 weeks when assessed at 48 hours after drug administration or infestation.

h. **Laboratory Dose Confirmation Study S12066-02: **Amblyomma americanum** Ticks

(1) **Title/Objective**
Effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs at the proposed recommended dose against *Amblyomma americanum* infestations in dogs determined at 72 hours after infestation

(2) **Location and Dates**
BerTek, Inc., Greenbrier, AR
April 28, 2012, to July 10, 2012

(3) **Study Design**
(a) **Study Animals**
18 healthy dogs (mostly Beagles and Hound crosses, 10 males and 8 females), 0.7 to 10 years of age, and 4.2 to 12.1 kg body weight

(b) **Experimental Design**
Prior to allocation to treatment groups on Day -7, an initial tick infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). Dogs were ranked and blocked by live tick count, and one dog from each block was randomly assigned to the untreated control (9 dogs) or the fluralaner (9 dogs) treatment group.

Drug administration was on Day 0. Tick infestations were conducted on Days -2, 28, and 56. At each infestation, each dog was infested with approximately 50 adult, unfed *A. americanum* ticks.

(c) **Drug Administration**
On Day 0, the nine dogs in the fluralaner group were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 26.5 to 40.2 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.
(d) Measurements and Observations
The primary variables for effectiveness were the counts of live ticks collected from the dogs. At tick counts on Days 3, 31, and 59, ticks were removed and the numbers of live and dead ticks were recorded. General health observations were conducted daily and at 1, 3, and 6 hours after drug administration. Dogs were weighed on Day -1. Tick counts and health observations were conducted masked to treatment.

(e) Statistical Methods
A mixed model analysis was used to analyze log-transformed tick counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results
At each tick count day, at least 7 of the 9 dogs in the control group each had an adequate infestation, defined as at least 13 live *A. americanum* ticks (25% of the infestations of 50 ticks per dog).

The fluralaner group had greater than 90% reduction in live tick counts at 72 hours following treatment or infestation for 8 weeks (infestation on Day 56).

On all count days following drug administration, live tick counts for the fluralaner group were significantly different from the control group (p < 0.001).

**Table 25: *A. americanum* S12066-02 Live Tick Count Effectiveness**

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Live Tick Counts(a)</th>
<th>Fluralaner Group Live Tick Counts(a)</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>21.6</td>
<td>0.3</td>
<td>98.8</td>
</tr>
<tr>
<td>31</td>
<td>17.9</td>
<td>0.2</td>
<td>98.8</td>
</tr>
<tr>
<td>59</td>
<td>17.6</td>
<td>1.6</td>
<td>90.8</td>
</tr>
</tbody>
</table>

\(a\) Tick counts are geometric means and % effectiveness is based on geometric means.

On all count days following drug administration, dead tick counts for the fluralaner group were significantly different from the control group (p < 0.001).

**Table 26: *A. americanum* S12066-02 Dead Tick Count Results**

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Dead Tick Counts(a)</th>
<th>Fluralaner Group Dead Tick Counts(a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>0.1</td>
<td>14.8</td>
</tr>
<tr>
<td>31</td>
<td>0.3</td>
<td>9.4</td>
</tr>
<tr>
<td>59</td>
<td>0.7</td>
<td>12.2</td>
</tr>
</tbody>
</table>

\(a\) Tick counts are geometric means.

(5) Adverse Reactions
No adverse reactions were reported in this study.
(6) Conclusion
This study demonstrated the effectiveness of fluralaner for the control (reduced live ticks) and treatment (increased dead ticks) of *A. americanum* ticks for 8 weeks when assessed at 72 hours after drug administration or infestation.

i. Laboratory Dose Confirmation Study S13080-01: *Amblyomma americanum* Ticks

(1) Title/Objective
Effectiveness of 13.64% w/w fluralaner flavored chewable tablets for dogs at the proposed recommended dose against wild caught *Amblyomma americanum* ticks on dogs

(2) Location and Dates
Young Veterinary Research Services, Turlock CA
April 13, 2013, to July 18, 2013

(3) Study Design
(a) Study Animals
20 healthy dogs (pure- and mixed-bred, 11 males and 9 females), 1.3 to 11.1 years of age, and 7.8 to 39.6 kg body weight

(b) Experimental Design
Prior to allocation to treatment groups on Day -6, an initial tick infestation and count was conducted to evaluate susceptibility of each dog to experimental infestation (host suitability). Dogs were ranked and blocked by live tick count, and one dog from each block was randomly assigned to the untreated control (10 dogs) or the fluralaner (10 dogs) treatment group.

Drug administration was on Day 0. Tick infestations were conducted on Days -2, 28, 55, and 83. At each infestation, each dog was infested with approximately 50 adult, unfed *A. americanum* ticks (approximate 50:50 ratio of male to female ticks).

(c) Drug Administration
On Day 0, the ten dogs in the fluralaner group were administered one or more whole fluralaner chews, at doses as close as possible to 25 mg/kg without under-dosing. Doses ranged from 25.3 to 34.2 mg/kg per dog. The chews were administered by placement on the back of the dog’s tongue (pilling) within 20 minutes after food had been offered.

(d) Measurements and Observations
The primary variables for effectiveness were the counts of live ticks collected from the dogs. At tick counts on Days 2, 30, 58 and 86, ticks were removed and the numbers of live and dead ticks were recorded. General health observations were conducted daily and at 1, 3, and 6
hours after drug administration. Dogs were weighed on Day -2. Tick counts and health observations were conducted masked to treatment.

(e) Statistical Methods

A mixed model analysis was used to analyze log-transformed tick counts, with treatment group as a fixed effect at a two-sided 5% significance level. Percent effectiveness against the control was calculated based on geometric means.

(4) Results

At each tick count day, all 10 dogs in the control group each had an adequate infestation, defined as at least 13 live *A. americanum* ticks (25% of the infestations of 50 ticks per dog).

The fluralaner group had greater than 90% reduction in live tick counts at 72 hours following treatment or infestation at 8 weeks (infestation on Day 55), but failed to demonstrate greater than 90% effectiveness beyond 8 weeks.

On all count days following drug administration, live tick counts for the fluralaner group were significantly different from the control group (p < 0.001).

Table 27: *A. americanum* S13080-01 Live Tick Count Effectiveness

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Live Tick Countsa</th>
<th>Fluralaner Group Live Tick Countsa</th>
<th>% Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>44.0</td>
<td>0.3</td>
<td>99.4</td>
</tr>
<tr>
<td>30</td>
<td>30.3</td>
<td>1.1</td>
<td>96.3</td>
</tr>
<tr>
<td>58</td>
<td>31.6</td>
<td>0.7</td>
<td>97.7</td>
</tr>
<tr>
<td>86</td>
<td>25.5</td>
<td>4.2</td>
<td>83.6</td>
</tr>
</tbody>
</table>

a Tick counts are geometric means and % effectiveness is based on geometric means.

On all count days following drug administration, dead tick counts for the fluralaner group were significantly different from the control group (p < 0.001).

Table 28: *A. americanum* S13080-01 Dead Tick Count Results

<table>
<thead>
<tr>
<th>Day for Tick Counts</th>
<th>Control Group Dead Tick Countsa</th>
<th>Fluralaner Group Dead Tick Countsa</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>0</td>
<td>24.4</td>
</tr>
<tr>
<td>30</td>
<td>0</td>
<td>13.3</td>
</tr>
<tr>
<td>58</td>
<td>0</td>
<td>12.0</td>
</tr>
<tr>
<td>86</td>
<td>0</td>
<td>6.8</td>
</tr>
</tbody>
</table>

a Tick counts are geometric means.

(5) Adverse Reactions

No adverse reactions were reported in this study.
(6) Conclusion

This study demonstrated the effectiveness of fluralaner for the control (reduced live ticks) and treatment (increased dead ticks) of *A. americanum* ticks for 8 weeks when assessed at 72 hours after drug administration or infestation, but failed to demonstrate greater than 90% effectiveness beyond 8 weeks.

III. TARGET ANIMAL SAFETY

A. Margin of Safety Study D009\11-001

1. Title/Objective

   Title: Target animal safety study in pups when administered 13.64% w/w fluralaner flavored chewable tablets for dogs orally on three occasions 56 days apart

   Study D009\11-001 assessed the safety of fluralaner chews following oral administration at doses of up to 1X, 3X, and 5X the maximum label dose (up to 56, 168, and 280 mg/kg) to dogs three times at eight-week intervals.

2. Location and Dates

   Charles River Laboratories Preclinical Services Ireland Ltd.
   Glenamoy, Co. Mayo, Ireland
   July 26, 2011, to February 7, 2012

3. Study Design

   a. Study Animals

   32 healthy weaned puppies (Beagles, 16 male and 16 female), 54 to 62 days of age, and 2.0 to 3.6 kg body weight

   b. Experimental Design

   Dogs were randomized to one of four treatment groups of eight dogs per group (four per sex) within sex by body weight. Dogs were either administered fluralaner chews at up to 56, 168, and 280 mg/kg (1X, 3X, and 5X the maximum label dose) three times at eight-week intervals (Study Days 0, 56, and 112) or were untreated (control group).

   c. Drug Administration

   The dogs were fed prior to oral administration of fluralaner chews.

   d. Measurements and Observations

   Clinical observations were made twice daily and at 1, 2, 3, 4, and 8 hours after oral administration of fluralaner chews on Study Days 0, 56, and 112. Body weight was recorded weekly. Individual food consumption was recorded daily. Blood samples were collected for clinical pathology (hematology, coagulation profile, clinical chemistry, adrenocorticotrophic hormone, and acute phase (C-reactive) protein) on Days -14, 8, 50, 106, and 162; and for plasma fluralaner concentrations on Study Days -5, 2, 7, 14, 28, 55, 58, 63, 70, 84, 111, 114, 119, 126, 140, and 167. Urine samples were collected...
overnight for urinalysis on Days -6/5, 7/8, 49/50, 105/106, and 161/162. All dogs were euthanized on Day 168 and underwent full gross necropsy, organ weight, and histopathological evaluation. Except for histopathological evaluation, measurements and observations were conducted masked to treatment.

4. Statistical Methods

Hematology, clinical chemistry, ACTH, coagulation, C-reactive protein, numerical urinalysis variables, food consumption, and body weight were analyzed using a repeated measured mixed model analysis of covariance. Pre-treatment measurement was included as a covariate. Organ weights were analyzed using a mixed model analysis of variance.

5. Results

There were no clinically-relevant, treatment-related effects on physical examinations, body weights, food consumption, clinical pathology (hematology, clinical chemistries, coagulation profiles and urinalysis), gross pathology, histopathology, or organ weights.

Diarrhea, mucoid and bloody feces were the most common observations in this study, occurring at a similar incidence in the treated and control groups. Five of the twelve treated dogs that experienced one or more of these signs did so within 6 hours of the first dosing. One dog in the 3X group was observed to be dull, inappetent, with evidence of bloody diarrhea, vomiting and weight loss beginning five days following the first dose. One dog in the 1X group vomited food four hours following the first dose.

Plasma concentrations of fluralaner confirmed systemic exposure of all treated dogs although the exposure was less than dose proportional. Dogs achieved steady-state fluralaner concentrations by the third treatment period.

6. Conclusion

The oral administration of fluralaner chews at up to 280 mg/kg on three occasions eight weeks apart was well-tolerated in dogs. Potential treatment-related effects include diarrhea, mucoid and bloody feces, and vomiting.

B. Reproductive Safety Study 671596

1. Title/Objective

Title: 13.64% w/w fluralaner flavored chewable tablets for dogs: target animal reproductive safety study in the dog by oral administration

Study 671596 assessed the effects of fluralaner chews on reproductive performance and offspring viability in dogs following oral administration at doses of up to 3X of the maximum label dose (up to 168 mg/kg).

2. Location and Dates

Charles River Laboratories Preclinical Services Edinburgh Ltd.
Tranent, Scotland
3. Study Design

   a. Study Animals

      40 adult, intact, reproductively-sound dogs (Beagles, 20 male and 20 female), 2 to 6 years of age, and 7.2 to 15.7 kg body weight

      The dogs were healthy and had a breeding history of at least four pups weaned in at least two of the three previous litters with no congenital malformations in any pup.

   b. Experimental Design

      Dogs were randomized to two treatment groups of 20 dogs per group (ten per sex) based on animal ID number and blocked by same parent. The treated dogs were administered fluralaner chews at up to 168 mg/kg (3X the maximum label dose of 56 mg/kg) for three to four doses at 8-week intervals, starting approximately 12 weeks (males) or 4 weeks (females) prior to expected mating. The females continued to be dosed at 8-week intervals until weaning of the pups, and the males were treated until the females had littered. The control dogs remained untreated.

   c. Drug Administration

      The dogs were fed prior to oral administration of fluralaner chews.

   d. Measurements and Observations

      Clinical observations were made twice daily and at 1, 2, 3, 4, and 8 hours after treatment on Days 1, 57, 113, 169, and 226. Body weight was recorded weekly for adult dogs and pups. Food consumption was recorded daily for adults. Blood samples were collected from adult dogs for clinical pathology (hematology, coagulation profile, and clinical chemistry) during acclimation; and for plasma fluralaner concentrations 1, 3, 7, 14, and 28 days after each dose, unless necropsy occurred first. Reproductive performance (including monthly semen analysis) and litter data was also assessed. All surviving pups and adult females were euthanized between Days 50 and 71 of lactation, and adult male dogs were euthanized 1 to 6 weeks after pups were born. Gross necropsy and organ weights were assessed in all dogs, and histopathological examination was performed on selected tissues including reproductive organs and any tissues with gross lesions. Except for histopathological evaluation, measurements and observations were conducted masked to treatment.

4. Statistical Methods

   Pre-mating adult body weight and food consumption (for each sex separately) and sperm assessment were analyzed using a repeated measures mixed model analysis of covariance. Pre-treatment measurement was included as a covariate. Average puppy weight of litters and organ weights of adults were analyzed using a mixed model analysis of variance.

5. Results

   All females that were bred in this study became pregnant and were allowed to litter normally. Two total litter losses occurred in the control group and one in the fluralaner-treated group.
There were no clinically-relevant, treatment-related effects on the body weights, food consumption, reproductive performance, semen analysis, litter data, gross necropsy (adult dogs), or histopathology findings (adult dogs and puppies). One treated and one control dog experienced diarrhea on the day of dosing, and one adult treated dog suffered a seizure during the course of the study (46 days after the third dose). Abnormal salivation was observed on 17 occasions: in six treated dogs (11 occasions) after dosing and four control dogs (6 occasions).

The following abnormalities were noted in 7 pups from 2 of the 10 dams in only the treated group during gross necropsy examination: limb deformity (4 pups), enlarged heart (2 pups), enlarged spleen (3 pups), and cleft palate (2 pups). During veterinary examination at Week 7, two pups from the control group had inguinal testicles, and two and four pups from the treated group had inguinal and cryptorchid testicles, respectively. No undescended testicles were observed at the time of necropsy (Days 50 to 71).

Plasma concentrations of fluralaner confirmed systemic and continuous exposure of all treated dogs throughout the study period.

6. Conclusion

The repeated oral administration of fluralaner at a dose of up to 168 mg/kg was well tolerated in reproducing dogs. In adult dogs, potential treatment-related effects include seizures, diarrhea and salivation after dosing. In puppies, potential treatment–related effects include limb deformity, enlarged heart and spleen, and cleft palate.

IV. HUMAN FOOD SAFETY:

This drug is intended for use in dogs. Because this new animal drug is not intended for use in food producing animals, CVM did not require data pertaining to drug residues in food (i.e., human food safety) for approval of this NADA.

V. USER SAFETY:

The product labeling contains the following information regarding safety to humans handling, administering, or exposed to BRAVECTO:

Not for human use. Keep this and all drugs out of the reach of children. Keep the product in the original packaging until use, in order to prevent children from getting direct access to the product. Do not eat, drink or smoke while handling the product. Wash hands thoroughly with soap and water immediately after use of the product.

VI. AGENCY CONCLUSIONS:

The data submitted in support of this NADA satisfy the requirements of section 512 of the Federal Food, Drug, and Cosmetic Act and 21 CFR part 514. The data demonstrate that BRAVECTO, when used according to the label, is safe and effective for killing adult fleas and for the treatment and prevention of flea infestations (Ctenocephalides felis), and the treatment and control of tick infestations [Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick)] for 12 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater. BRAVECTO is also safe and effective for the
treatment and control of *Amblyomma americanum* (lone star tick) infestations for 8 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater.

A. **Marketing Status:**

This product may be dispensed only by or on the lawful order of a licensed veterinarian (Rx marketing status). Adequate directions for lay use cannot be written because professional expertise is required to advise dog owners regarding use in breeding dogs, to monitor for and respond to adverse reactions, and to define the appropriate treatment interval (8 vs. 12 weeks) based on the species of ticks the dog is likely to encounter.

B. **Exclusivity:**

BRAVECTO, as approved in our approval letter qualifies for FIVE years of marketing exclusivity beginning as of the date of our approval letter. This drug qualifies for exclusivity under section 512(c)(2)(F)(i) of the Federal Food, Drug, and Cosmetic Act because this is the first time we are approving this active ingredient in a new animal drug.

C. **Patent Information:**

For current information on patents, see the Animal Drugs @ FDA database or the Green Book on the FDA CVM internet website.

VII. **Appendix 1: Details of Correction**

In the Results section for Reproductive Safety Study 671596, the timing of the seizure experience by one adult treated dog was corrected from 46 days after the second dose to 46 days after the third dose. The correction was made on June 13, 2017.

The original text for the Results section:

5. Results

All females that were bred in this study became pregnant and were allowed to litter normally. Two total litter losses occurred in the control group and one in the fluralaner-treated group.

There were no clinically-relevant, treatment-related effects on the body weights, food consumption, reproductive performance, semen analysis, litter data, gross necropsy (adult dogs), or histopathology findings (adult dogs and puppies). One treated and one control dog experienced diarrhea on the day of dosing, and one adult treated dog suffered a seizure during the course of the study (46 days after the second dose). Abnormal salivation was observed on 17 occasions: in six treated dogs (11 occasions) after dosing and four control dogs (6 occasions).

The following abnormalities were noted in 7 pups from 2 of the 10 dams in only the treated group during gross necropsy examination: limb deformity (4 pups), enlarged heart (2 pups), enlarged spleen (3 pups), and cleft palate (2 pups). During veterinary examination at Week 7, two pups from the control group had inguinal testicles, and two and four pups from the treated group had inguinal and
cryptorchid testicles, respectively. No undescended testicles were observed at the time of necropsy (Days 50 to 71).

Plasma concentrations of fluralaner confirmed systemic and continuous exposure of all treated dogs throughout the study period.

Corrected text for the Results section:

5. Results

All females that were bred in this study became pregnant and were allowed to litter normally. Two total litter losses occurred in the control group and one in the fluralaner-treated group.

There were no clinically-relevant, treatment-related effects on the body weights, food consumption, reproductive performance, semen analysis, litter data, gross necropsy (adult dogs), or histopathology findings (adult dogs and puppies). One treated and one control dog experienced diarrhea on the day of dosing, and one adult treated dog suffered a seizure during the course of the study (46 days after the third dose). Abnormal salivation was observed on 17 occasions: in six treated dogs (11 occasions) after dosing and four control dogs (6 occasions).

The following abnormalities were noted in 7 pups from 2 of the 10 dams in only the treated group during gross necropsy examination: limb deformity (4 pups), enlarged heart (2 pups), enlarged spleen (3 pups), and cleft palate (2 pups). During veterinary examination at Week 7, two pups from the control group had inguinal testicles, and two and four pups from the treated group had inguinal and cryptorchid testicles, respectively. No undescended testicles were observed at the time of necropsy (Days 50 to 71).

Plasma concentrations of fluralaner confirmed systemic and continuous exposure of all treated dogs throughout the study period.